Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Average Rating of “Hold” from Brokerages

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been assigned a consensus recommendation of “Hold” from the seven brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have issued a buy rating on the company. The average 12-month price objective among analysts that have covered the stock in the last year is $4.25.

Several equities analysts have recently commented on the stock. HC Wainwright lowered their price target on shares of Inovio Pharmaceuticals from $3.00 to $2.50 and set a “neutral” rating for the company in a research report on Monday, June 1st. Weiss Ratings lowered shares of Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, July 1st. Finally, Wall Street Zen cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, June 21st.

Inovio Pharmaceuticals Price Performance

NASDAQ:INO opened at $1.12 on Friday. The firm has a market capitalization of $92.14 million, a P/E ratio of -0.77 and a beta of 1.48. The business has a 50 day simple moving average of $1.19 and a 200 day simple moving average of $1.40. Inovio Pharmaceuticals has a 12-month low of $1.03 and a 12-month high of $2.98.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its earnings results on Wednesday, May 13th. The biopharmaceutical company reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.30) by $0.02. Research analysts anticipate that Inovio Pharmaceuticals will post -0.97 EPS for the current fiscal year.

Hedge Funds Weigh In On Inovio Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in INO. AQR Capital Management LLC bought a new stake in Inovio Pharmaceuticals during the 1st quarter valued at $120,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Inovio Pharmaceuticals by 39.6% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 20,781 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 5,894 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in shares of Inovio Pharmaceuticals during the second quarter valued at about $234,000. Jane Street Group LLC lifted its holdings in Inovio Pharmaceuticals by 221.2% in the second quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 27,329 shares during the period. Finally, JPMorgan Chase & Co. lifted its holdings in Inovio Pharmaceuticals by 1,667.1% in the third quarter. JPMorgan Chase & Co. now owns 65,206 shares of the biopharmaceutical company’s stock worth $153,000 after purchasing an additional 61,516 shares during the period. 26.79% of the stock is owned by institutional investors.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.